Fate Therapeutics Inc. buy Barclays PLC
Start price
27.02.24
/
50%
€6.42
Target price
27.02.25
€9.22
Performance (%)
-42.40%
Price
30.04.24
€3.70
Summary
This prediction is currently active. The BUY prediction by Barclays_PLC for Fate Therapeutics Inc. is performing very badly with a performance of -42.40%. This prediction currently runs until 27.02.25. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Fate Therapeutics Inc. | -8.103% | -8.103% |
| iShares Core DAX® | -0.992% | -3.231% |
| iShares Nasdaq 100 | -0.225% | -3.339% |
| iShares Nikkei 225® | -0.736% | -7.859% |
| iShares S&P 500 | -0.509% | -2.979% |
Comments by Barclays_PLC for this prediction
In the thread Fate Therapeutics Inc. diskutieren
Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat